| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Observational Study |
| Article Title |
Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hsin‐Yun Sun, Chien-Yu Cheng, Chi-Ying Lin, Chia‐Jui Yang, Nan-Yao Lee, Bo-Huang Liou, Hung-Jen Tang, Yuang-Meng Liu, Chun-Yuan Lee, Tun-Chieh Chen, Yi-Chia Huang, Yuan-Ti Lee, Ming-Jui Tsai, Po-Liang Lu, Hung-Chin Tsai, Ning-Chi Wang, Tung-Che Hung, Shu-Hsing Cheng and Chien‐Ching Hung |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Taiwan University Hospital, Taipei, Taiwan |
NTUH106-003347 |
|
| Corresponding Author |
Chien‐Ching Hung, MD, PhD, Doctor, Doctor, Full Professor, Staff Physician, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7 Chung-Shan South Road, Taipei 110, Taiwan. hcc0401@ntu.edu.tw |
| Key Words |
Viral hepatitis; End-of-treatment response; Sustained virologic response; People who inject drugs; Antiretroviral therapy; Tenofovir |
| Core Tip |
Similar to the observation made in human immunodeficiency virus-negative patients, virologic response 12 wk off-therapy achieved with direct-acting antivirals (DAAs) was high in human immunodeficiency virus-positive patients coinfected with hepatitis C virus genotype 6. Estimated glomerular filtration rate declined with DAA initiation in patients receiving sofosbuvir and tenofovir disoproxil fumarate or tenofovir alafenamide, which recovered after the completion of DAA treatment. |
| Publish Date |
2022-03-17 03:25 |
| Citation |
Sun HY, Cheng CY, Lin CY, Yang CJ, Lee NY, Liou BH, Tang HJ, Liu YM, Lee CY, Chen TC, Huang YC, Lee YT, Tsai MJ, Lu PL, Tsai HC, Wang NC, Hung TC, Cheng SH, Hung CC. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections. World J Gastroenterol 2022; 28(11): 1172-1183 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i11/1172.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i11.1172 |
